dc.contributor.author | Bilici, Ahmet | |
dc.contributor.author | Uysal, Mükremin | |
dc.contributor.author | Menekşe, Serkan | |
dc.contributor.author | Akın, Semih | |
dc.contributor.author | Yıldız, Fatih | |
dc.contributor.author | Turan, Merve | |
dc.contributor.author | Sezgin Göksu, Sema | |
dc.contributor.author | Beypınar, İsmail | |
dc.contributor.author | Sakalar, Teoman | |
dc.contributor.author | Değirmenci, Mustafa | |
dc.contributor.author | Erdem, Dilek | |
dc.contributor.author | Başaran, Gül | |
dc.contributor.author | Ölmez, Ömer Fatih | |
dc.contributor.author | Avcı, Nilüfer | |
dc.contributor.author | Tural, Deniz | |
dc.contributor.author | Sakin, Abdullah | |
dc.contributor.author | Türker, Sema | |
dc.contributor.author | Demir, Atakan | |
dc.contributor.author | Temiz, Süleyman | |
dc.contributor.author | Kaplan, Muhammed Ali | |
dc.contributor.author | Doğan, Mutlu | |
dc.contributor.author | Tanrıverdi, Özgür | |
dc.contributor.author | Bilgetekin, İrem | |
dc.contributor.author | Yeşil Çınkır, Havva | |
dc.contributor.author | Açıkgöz, Özgür | |
dc.contributor.author | Paydaş, Semra | |
dc.contributor.author | Uslu, Rüçhan | |
dc.contributor.author | Turhal, Serdar | |
dc.date.accessioned | 2023-01-10T13:00:49Z | |
dc.date.available | 2023-01-10T13:00:49Z | |
dc.date.issued | 2022 | en_US |
dc.identifier.citation | Bilici, A., Uysal, M., Menekşe, S., Akın, S., Yıldız, F., Turan, M. ... Turhal, S. (2022). Real-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) study. Cancer Investigation, 40(2), 199-209. https://dx.doi.org/10.1080/07357907.2021.2017952 | en_US |
dc.identifier.issn | 0735-7907 | |
dc.identifier.issn | 1532-4192 | |
dc.identifier.uri | https://dx.doi.org/10.1080/07357907.2021.2017952 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/10281 | |
dc.description.abstract | Purpose: This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) metastatic breast cancer (MBC) patients in real-life settings. Methods: Overall, 204 HR+, HER2− MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included. Overall survival (OS) and progression-free survival (PFS) and safety data were analyzed. Results: The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively. Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response (p = 0.035) and PFS (p = 0.024). The presence of bone-only metastasis was associated with better treatment response (p = 0.002), PFS (p < 0.001), and OS (p = 0.001). Conclusion: We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER − MBC patients. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Taylor & Francis Inc | en_US |
dc.rights | info:eu-repo/semantics/embargoedAccess | en_US |
dc.subject | Everolimus | en_US |
dc.subject | Exemestane | en_US |
dc.subject | Metastatic Breast Cancer | en_US |
dc.subject | Hormone Receptor-Positive | en_US |
dc.subject | HER Negative | en_US |
dc.subject | Efficacy | en_US |
dc.title | Real-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) study | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Cancer Investigation | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-0443-6966 | en_US |
dc.authorid | 0000-0001-7934-7039 | en_US |
dc.authorid | 0000-0003-2715-4002 | en_US |
dc.identifier.volume | 40 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.startpage | 199 | en_US |
dc.identifier.endpage | 209 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1080/07357907.2021.2017952 | en_US |
dc.institutionauthor | Bilici, Ahmet | |
dc.institutionauthor | Ölmez, Ömer Fatih | |
dc.institutionauthor | Açıkgöz, Özgür | |
dc.identifier.wosquality | Q4 | en_US |
dc.identifier.wos | 000734258300001 | en_US |
dc.identifier.scopus | 2-s2.0-85121803055 | en_US |
dc.identifier.pmid | 34894960 | en_US |
dc.identifier.scopusquality | Q2 | en_US |